BioXcel Therapeutics
BTAI
108 hedge funds and large institutions have $378M invested in BioXcel Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 32 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 32
0.13% more ownership
Funds ownership: 2.8% → 2.93% (+0.13%)
7% less funds holding
Funds holding: 116 → 108 (-8)
20% less capital invested
Capital invested by funds: $475M → $378M (-$96.5M)
25% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 32
38% less call options, than puts
Call options by funds: $4.94M | Put options by funds: $7.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.2M |
| 2 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$9.34M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$7.91M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$7.67M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$17.3M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$15.5M |
| 3 |
LCG
Lisanti Capital Growth
New York
|
-$4.01M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$1.73M |
| 5 |
ACA
Apis Capital Advisors
New York
|
-$1.55M |
BTAI Hedge Fund Activity: Q2 2021 in Review
108 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2021, worth a combined $378M — down 20% from $475M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of BTAI and 24 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 37 added.
The largest buyer was Fidelity Investments, adding an estimated $30.2M. The largest seller was Logos Global Management, exiting entirely with an estimated $17.3M sold.
- 108 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2021, down from 116 in Q1 2021.
- Funds reported $378M of BioXcel Therapeutics stock for Q2 2021, down 20% quarter-over-quarter.
- 24 funds opened new BioXcel Therapeutics positions in Q2 2021 and 32 closed out, a net change of -8 holders.
- The largest BioXcel Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $30.2M added.
- The largest BioXcel Therapeutics seller in Q2 2021 was Logos Global Management, an estimated $17.3M sold.
Based on aggregated 13F filings for Q2 2021.